These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 3300710)

  • 21. Clinical trial of combined hormone therapy (MAP + TAM) for metastatic breast cancer.
    Pannuti F; Martoni A; Piana E; Tomasi L; Grieco A; Farris A; Saccani F; Baroni M
    Chemioterapia; 1984 Aug; 3(4):211-5. PubMed ID: 6241846
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Controversy over cancer chemotherapy in Japan.
    Kawabata H; Ueno T
    Lancet; 1999 Jun; 353(9169):2077. PubMed ID: 10376656
    [No Abstract]   [Full Text] [Related]  

  • 23. Optimal regimen for treatment-naive hormone receptor-positive HER-2 negative metastatic breast cancer.
    Bilgin B; Şendur MA; Hızal M; Akıncı MB; Dede DŞ; Yalçın B
    Future Oncol; 2019 Jan; 15(2):105-107. PubMed ID: 30484708
    [No Abstract]   [Full Text] [Related]  

  • 24. New developments in adjuvant therapy for breast cancer.
    Sledge GW
    Clin Adv Hematol Oncol; 2005 Sep; 3(9):688-90. PubMed ID: 16224442
    [No Abstract]   [Full Text] [Related]  

  • 25. [Tumor specific therapy. Targeted breast cancer therapy].
    MMW Fortschr Med; 2003 Sep; 145(38):62. PubMed ID: 14603691
    [No Abstract]   [Full Text] [Related]  

  • 26. [French FAC vs FEC study in advanced breast cancer].
    Keiling R; Armand PP; Hurteloup P; Cappelaere P
    Onkologie; 1986 Aug; 9 Suppl 1():8-10. PubMed ID: 3528969
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Paclitaxel in therapy of breast carcinoma. Value and perspectives].
    Klaassen U; Seeber S
    Med Klin (Munich); 1996 Dec; 91 Suppl 2():7-10. PubMed ID: 9082172
    [No Abstract]   [Full Text] [Related]  

  • 28. [Adjuvant therapies in breast carcinoma].
    Joss R; Brunner K
    Schweiz Rundsch Med Prax; 1991 Mar; 80(11):247-54. PubMed ID: 2024099
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [The use of high-dose chemotherapy in the treatment of breast cancer].
    Espinosa E; Zamora P; González Barón M
    Med Clin (Barc); 1996 Jun; 107(2):56-8. PubMed ID: 8753896
    [No Abstract]   [Full Text] [Related]  

  • 30. Chemotherapy benefits nearly all early breast cancer patients.
    McNeil C
    J Natl Cancer Inst; 1997 Jun; 89(12):838-9. PubMed ID: 9196246
    [No Abstract]   [Full Text] [Related]  

  • 31. [Metastatic cancer of the breast. Study of intensive induction of remission chemotherapy. Controlled clinical trial].
    Jouve M; Palangie T; Dorval T; Garcia-Giral E; Asselain B; Coutant M; Pouillart P
    Bull Cancer; 1986; 73(6):683-4. PubMed ID: 3552083
    [No Abstract]   [Full Text] [Related]  

  • 32. [Chemotherapy of primary and metastasizing breast cancer].
    Hofmann V; Martz G
    Gynakol Rundsch; 1984; 24 Suppl 1():78-86. PubMed ID: 6394442
    [No Abstract]   [Full Text] [Related]  

  • 33. Re: Polychemotherapy for early breast cancer: results from the international adjuvant breast cancer chemotherapy randomized Trial.
    Ferretti G; Felici A; Carlini P; Cognetti F
    J Natl Cancer Inst; 2007 Sep; 99(18):1416. PubMed ID: 17848675
    [No Abstract]   [Full Text] [Related]  

  • 34. Weekly low-dose doxorubicin with or without high-dose medroxyprogesterone acetate as secondary treatment in metastatic breast cancer--a randomized trial.
    Elomaa I; Blomqvist C; Rissanen P; Mäntylä M
    Acta Oncol; 1988; 27(3):297-9. PubMed ID: 2970862
    [No Abstract]   [Full Text] [Related]  

  • 35. Management of patients with breast cancer: from chemotherapy to stem cell support. Introduction.
    Gilbert CJ
    Pharmacotherapy; 1996; 16(3 Pt 2):85S-87S. PubMed ID: 8726586
    [No Abstract]   [Full Text] [Related]  

  • 36. Post-operative therapy of breast cancer: rationale for adjuvant chemotherapy.
    Butler WM
    J S C Med Assoc; 1984 Jan; 80(1):15-6. PubMed ID: 6371378
    [No Abstract]   [Full Text] [Related]  

  • 37. Refining systemic therapy for early breast cancer: difficulties with subtraction.
    Dodwell D; Thorpe H; Coleman R
    Lancet Oncol; 2009 Aug; 10(8):738-9. PubMed ID: 19647192
    [No Abstract]   [Full Text] [Related]  

  • 38. High-dose chemotherapy for breast cancer.
    Antman KH; Heitjan DF; Hortobagyi GN
    JAMA; 1999 Nov; 282(18):1701-3. PubMed ID: 10568629
    [No Abstract]   [Full Text] [Related]  

  • 39. [Breast carcinoma. Preoperative chemotherapy can preserve the breast].
    MMW Fortschr Med; 2002 Oct; 144(42):63. PubMed ID: 12534003
    [No Abstract]   [Full Text] [Related]  

  • 40. [The optimal duration of adjuvant therapy in breast cancer: what kind of evidence? Chemotherapy: the example of clinical studies].
    Sdrobolini A
    Suppl Tumori; 2004; 3(4):S77-8. PubMed ID: 15206220
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.